Full Press Release Details
NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases
QuantalX's direct electrophysiology imaging
technology (Delphi-MD) expected to provide multiple clinically objective and accurate measurements in NeuroSense's Phase 2 double-blind
proof-of-concept clinical study in Alzheimer's disease, expected to commence in H1 2023
CAMBRIDGE, Mass. and KFAR SABA, Israel, Feb.
9, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a clinical-stage drug development company and QuantalX
Neuroscience Ltd; the developer of Delphi-MD, a clinically objective neurodiagnostic medical device, announced today a collaboration
to improve early diagnosis and treatment of neurodegenerative diseases. The NeuroSense-QuantalX collaboration comes following NeuroSense's
recent report on new biomarker data in Alzheimer's disease (AD) and its plans to initiate a Phase 2 AD clinical trial
in the first half of 2023.
QuantalX's Delphi-MD is a breakthrough technology
that supports clinicians' neurodiagnostic gaps at the point of care through real-time monitoring of brain functionality, resulting in
improved patient care and reduced associated financial burden. Delphi-MD is expected to provide multiple clinically objective and accurate
measurements of brain function in a safe and simple manner in NeuroSense's upcoming AD Phase 2 clinical trial.
In addition, the companies agreed that QuantalX's
Delphi-MD will be used for early diagnosis and ongoing monitoring of trial participants in NeuroSense's planned future pivotal Phase 3
efficacy trial of PrimeC in people living with amyotrophic lateral sclerosis (ALS), pending the successful conclusion of its ALS Phase
"We're humbled and excited to join NeuroSense
in its effort to advance therapies for neurodegenerative diseases, empowering neurologists to provide better patient care through early
detection and personalized disease management," said Dr. Iftach Dolev, QuantalX CEO and Co-Founder.
"We believe the use of cutting-edge innovations
like Delphi-MD is the future of early detection and treatment of neurodegenerative diseases. We are enthusiastic to work with QuantalX,
whose technology complements our extensive evaluation of our platform combination drug therapy via clinical measurements and a large panel
of biomarkers," said NeuroSense CEO Alon Ben-Noon. "We envision a long-term collaboration beginning with our upcoming Phase
2 double-blind clinical study in Alzheimer's disease, which we plan to commence in the first half of this year."
About Alzheimer's Disease
Alzheimer's disease (AD) is the most common form
of progressive dementia, affecting 5-10% of the population over 65 years of age, with prevalence estimates increasing exponentially with
age (Singh and Fudenberg 1988). Clinically, it is characterized by a progressive deterioration of cognition, predominantly affecting episodic
memory, but also resulting in loss of insight, judgment, language, changes in perception, praxis (the ability to perform day-to-day tasks),
behavior, lack of sleep, mood swings, and in late stages, physical functioning (Chouraki and Seshadri 2014). The global AD treatment market
is expected to grow to $5 billion in 2022.
Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5
years from diagnosis. Every year, more than 5,000 patients are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1
billion. The number of patients with ALS is expected to grow 24% by 2040 in the U.S. and EU.
PrimeC, NeuroSense's lead drug candidate, is a novel
extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib.
PrimeC is designed to synergistically target several key mechanisms of amyotrophic lateral sclerosis (ALS) that contribute to motor neuron
degeneration, inflammation, iron accumulation and impaired RNA regulation to potentially inhibit the progression of ALS. NeuroSense completed
a Phase 2a clinical study which successfully met its safety and efficacy endpoints including reducing functional and respiratory deterioration
and statistically significant changes in ALS-related biological markers indicating PrimeC's biological activity. Through a collaboration
with Massachusetts General Hospital in Boston on novel Neuron-Derived Exosomes (NDEs), NeuroSense is working to further determine
the biological changes in ALS-related pathologies and the effect of PrimeC on relevant targets. PrimeC was granted Orphan Drug Designation
by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
The Delphi-MD medical device provides definitive
and quantitative, real-time brain function analysis through a first-in-class direct brain network visualization technology. The device
magnetically stimulates healthy or symptomatic patients' brain networks in a simple point of care affordable test, to enable early detection
and differential diagnosis of brain abnormalities.
QuantalX Neuroscience, Ltd. is dedicated to tackling
current brain health challenges leading to late diagnosis and misdiagnosis of neurodegenerative diseases. Delphi-MD's breakthrough technology
supports clinicians' neurodiagnostic gaps at the point of care through real-time monitoring of brain functionality; resulting in improved
patient care and reduction of associated financial burden. For more information visit https://quantalx.com/ and
follow QuantalX on LinkedIn.
About NeuroSense Therapeutics
NeuroSense Therapeutics, Ltd. is a clinical-stage
biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases.
NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease,
among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available
for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of
related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit
Forward-Looking Statements
This press release contains "forward-looking
statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained
in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by
the use of words such as "anticipate," "believe," "contemplate," "could," "estimate,"
"expect," "intend," "seek," "may," "might," "plan," "potential,"
"predict," "project," "target," "aim," "should," "will" "would,"
or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking
statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions
that are difficult to predict and include statements regarding the company's PrimeC and Alzheimer's development programs; the timing of
completion of the Company's Phase 2b study and report of topline results; the potential for PrimeC to safely and effectively
target ALS; preclinical and clinical data for PrimeC; the timing of current and future clinical trials, including future phase 3, timing
for reporting data; cash runway estimates; the nature, strategy and focus of the company and further updates with respect thereto; and
the development and commercial potential of any product candidates of the company. Such risks and uncertainties include the risk
that QuantalX's Delphi-MD will not successfully provide clinically objective and accurate measurements of NeuroSense's AD Phase 2 clinical
trial, there will a delay in the timing of commencement of the Company's AD Phase 2 clinical trial and the report of topline
results, and other risks and uncertainties set forth in the Company's filings with the Securities and Exchange Commission (SEC),
including the Company's Annual Report on Form 20-F filed with the SEC on April 14, 2022. Further, certain forward-looking
statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this
announcement are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty to update such information except as required
under applicable law.